Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy2018-01-17T17:04:58-05:00
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines2018-01-17T17:04:58-05:00
The reproductive effects of beta interferon therapy in pregnancy The reproductive effects of beta interferon therapy in pregnancy2018-01-17T17:04:53-05:00
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients2018-01-17T17:04:53-05:00
Key issues in the diagnosis and treatment of multiple sclerosis Key issues in the diagnosis and treatment of multiple sclerosis2018-01-17T17:04:46-05:00
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis2018-01-17T17:04:46-05:00
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis2018-01-17T17:04:46-05:00
Using stem cells in multiple sclerosis therapies Using stem cells in multiple sclerosis therapies2018-01-17T17:04:40-05:00
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses2018-01-17T17:04:40-05:00
